These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 38872714)

  • 1.
    García-Castillo M; Hernández-García M; Correa A; Coppi M; Griener T; Fritsche T; Pitart C; Sampaio J; Seifert H; Wake K; Wootton M; Vila J; Cantón R
    JAC Antimicrob Resist; 2024 Jun; 6(3):dlae088. PubMed ID: 38872714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity and resistance rates of topical antimicrobials fusidic acid, mupirocin and ozenoxacin against skin and soft tissue infection pathogens obtained across Canada (CANWARD 2007-18).
    Zhanel GG; Adam HJ; Baxter M; Lagace-Wiens PRS; Karlowsky JA
    J Antimicrob Chemother; 2021 Jun; 76(7):1808-1814. PubMed ID: 33792700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro antimicrobial activity of ozenoxacin against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus and Streptococcus pyogenes isolated from clinical cutaneous specimens in Japan.
    Kanayama S; Ikeda F; Okamoto K; Nakajima A; Matsumoto T; Ishii R; Amano A; Matsuzaki K; Matsumoto S
    J Infect Chemother; 2016 Oct; 22(10):720-3. PubMed ID: 27091753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of ceftaroline against bacterial isolates causing skin and soft tissue and respiratory tract infections collected in Latin American countries, ATLAS program 2016-2020.
    Mohamed N; Valdez RR; Fandiño C; Baudrit M; Falci DR; Murillo JDC
    J Glob Antimicrob Resist; 2024 Mar; 36():4-12. PubMed ID: 38016592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of ceftaroline against bacterial pathogens isolated from skin and soft tissue infections in Europe, Russia and Turkey in 2012: results from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance programme.
    Karlowsky JA; Biedenbach DJ; Bouchillon SK; Iaconis JP; Reiszner E; Sahm DF
    J Antimicrob Chemother; 2016 Jan; 71(1):162-9. PubMed ID: 26503667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of retapamulin against linezolid and methicillin-resistant Staphylococcus aureus isolates.
    Candel FJ; Morales G; Picazo JJ
    Rev Esp Quimioter; 2011 Sep; 24(3):127-30. PubMed ID: 21947094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).
    Sader HS; Flamm RK; Jones RN
    Diagn Microbiol Infect Dis; 2013 May; 76(1):61-8. PubMed ID: 23535208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
    Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
    J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of retapamulin against Staphylococcus aureus isolates resistant to fusidic acid and mupirocin.
    Woodford N; Afzal-Shah M; Warner M; Livermore DM
    J Antimicrob Chemother; 2008 Oct; 62(4):766-8. PubMed ID: 18567573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--I. Gram-positive bacteria].
    Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
    Jpn J Antibiot; 2003 Oct; 56(5):437-57. PubMed ID: 14692380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017.
    Huband MD; Pfaller MA; Shortridge D; Flamm RK
    J Glob Antimicrob Resist; 2019 Dec; 19():56-63. PubMed ID: 30825698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of eravacycline and comparators against Gram-negative and Gram-positive bacterial isolates collected from patients globally between 2017 and 2020.
    Hawser S; Kothari N; Monti F; Morrissey I; Siegert S; Hodges T
    J Glob Antimicrob Resist; 2023 Jun; 33():304-320. PubMed ID: 37207925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
    Noviello S; Ianniello F; Leone S; Esposito S
    J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009-13).
    Sader HS; Farrell DJ; Flamm RK; Jones RN
    J Antimicrob Chemother; 2015 Jul; 70(7):2053-6. PubMed ID: 25814163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in vitro antibacterial activity of ozenoxacin against Gram-positive clinical isolates.
    Canton R; Morrissey I; Vila J; Tato M; García-Castillo M; López Y; Gargallo-Viola D; Zsolt I
    Future Microbiol; 2018 May; 13():3-19. PubMed ID: 29745242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates.
    Sambatakou H; Giamarellos-Bourboulis EJ; Grecka P; Chryssouli Z; Giamarellou H
    J Antimicrob Chemother; 1998 Mar; 41(3):349-55. PubMed ID: 9578161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of ceftaroline and comparators against bacterial isolates collected globally from patients with skin infections.
    Piérard D; Stone GG
    J Glob Antimicrob Resist; 2021 Sep; 26():4-10. PubMed ID: 34022417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro Activity of Ceftaroline Against Isolates of Gram-Positive Bacteria from Patients with Bloodstream Infections Collected as a Part of ATLAS Between 2017 and 2020.
    Kempf M; Arhin FF; Kuraieva A; Utt E
    Infect Drug Resist; 2024; 17():343-354. PubMed ID: 38312522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vitro Antimicrobial Activities of Fusidic Acid and Retapamulin against Mupirocin- and Methicillin-Resistant Staphylococcus aureus.
    Park SH; Kim JK; Park K
    Ann Dermatol; 2015 Oct; 27(5):551-6. PubMed ID: 26512169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial susceptibility patterns and characterization of clinical isolates of Staphylococcus aureus in KwaZulu-Natal province, South Africa.
    Shittu AO; Lin J
    BMC Infect Dis; 2006 Jul; 6():125. PubMed ID: 16875502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.